BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29351916)

  • 1. Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.
    Asiedu MK; Thomas CF; Dong J; Schulte SC; Khadka P; Sun Z; Kosari F; Jen J; Molina J; Vasmatzis G; Kuang R; Aubry MC; Yang P; Wigle DA
    Clin Cancer Res; 2018 Apr; 24(7):1691-1704. PubMed ID: 29351916
    [No Abstract]   [Full Text] [Related]  

  • 2. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
    Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
    Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
    Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
    Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
    Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
    Swarts DR; Ramaekers FC; Speel EJ
    Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
    Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
    Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of mixed pulmonary carcinoma and carcinoid: the driver from their mono-clonal origin.
    Graziano P; Parente P; Centra F; Milione M; Centonze G; Volante M; Cavazza A; Urbano D; Di Maggio G; Balsamo T; Di Micco C; Rossi G; Rossi A; Muscarella LA
    Virchows Arch; 2024 Jan; 484(1):37-46. PubMed ID: 37773451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
    Voortman J; Lee JH; Killian JK; Suuriniemi M; Wang Y; Lucchi M; Smith WI; Meltzer P; Wang Y; Giaccone G
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13040-5. PubMed ID: 20615970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas.
    Gugger M; Burckhardt E; Kappeler A; Hirsiger H; Laissue JA; Mazzucchelli L
    J Pathol; 2002 Apr; 196(4):408-15. PubMed ID: 11920736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
    Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
    Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic changes in the spectrum of neuroendocrine lung tumors.
    Onuki N; Wistuba II; Travis WD; Virmani AK; Yashima K; Brambilla E; Hasleton P; Gazdar AF
    Cancer; 1999 Feb; 85(3):600-7. PubMed ID: 10091733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.
    Fujii K; Miyata Y; Takahashi I; Koizumi H; Saji H; Hoshikawa M; Takagi M; Nishimura T; Nakamura H
    Proteomics Clin Appl; 2018 Nov; 12(6):e1800015. PubMed ID: 29888431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular pathogenesis and management of bronchial carcinoids.
    Cakir M; Grossman A
    Expert Opin Ther Targets; 2011 Apr; 15(4):457-91. PubMed ID: 21275849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
    Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
    Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology.
    Cros J; Théou-Anton N; Gounant V; Nicolle R; Reyes C; Humez S; Hescot S; Thomas de Montpréville V; Guyétant S; Scoazec JY; Guyard A; de Mestier L; Brosseau S; Mordant P; Castier Y; Gentien D; Ruszniewski P; Zalcman G; Couvelard A; Cazes A
    Neuroendocrinology; 2021; 111(1-2):158-169. PubMed ID: 32015233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
    Sun TY; Hendifar A; Padda SK
    Curr Oncol Rep; 2022 Jul; 24(7):819-824. PubMed ID: 35305210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.